G9833 HCPCS Level II code: Patient transfer to practice after initiation of chemotherapy
CMS terminated G9833: its last date of service was Dec 31, 2020. It stays here for looking up older claims; newer services need a current code.
Official description
G9833Patient transfer to practice after initiation of chemotherapy
Short description: Transf pract aft init chemo
HCPCS · United States
Medicare details
The indicators CMS publishes with G9833 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)
- Type of service
- Medical care
- BETOS category
- Undefined codes
- Added
- Jan 1, 2017
- Terminated after
- Dec 31, 2020
Where G9833 sits
- 1G codesProcedures and professional services
- 2Terminated G9833Patient transfer to practice after initiation of chemotherapy
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code G9833 still valid?
No. CMS terminated G9833; its last date of service was Dec 31, 2020. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover G9833?
CMS lists G9833’s Medicare coverage as “Carrier judgment” and its pricing as “Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside G9833
All G codesG9827Her2-targeted therapies not administered during the initial course of treatmentG9828Her2-targeted therapies administered during the initial course of treatmentG9829Breast adjuvant chemotherapy administeredG9830Her-2/neu positiveG9831Ajcc stage at breast cancer diagnosis = ii or iiiG9832Ajcc stage at breast cancer diagnosis = i (ia or ib) and t-stage at breast cancer diagnosis = t1cG9834Patient has metastatic disease at diagnosisG9835Trastuzumab administered within 12 months of diagnosisG9836Reason for not administering trastuzumab documented (e.g. patient declined, patient died, patient transferred, contraindication or other clinical exclusion, neoadjuvant…G9837Trastuzumab not administered within 12 months of diagnosisG9838Patient has metastatic disease at diagnosisG9839Anti-egfr monoclonal antibody therapy